Last update 21 Nov 2024

C2L-OCT-01 PR

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms-
Target-
Mechanism-
Therapeutic Areas
Nervous System DiseasesEndocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases+ [1]
Active Indication-
Inactive Indication
Acromegaly
Originator Organization
Ambrilia Biopharma, Inc.
Active Organization-
Inactive Organization
Ambrilia Biopharma, Inc.
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

6
Clinical Trials associated with C2L-OCT-01 PR
NCT00642421 / TerminatedPhase 3
Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2l-OCT-01 PR, Administered Intra Muscularly Every 4, 5 or 6 Weeks in Acromegalic Patients
EUCTR2007-004320-21-HU / Not yet recruitingNot Applicable
OPEN LABEL EXTENSION STUDY EVALUATING THE SAFETY AND BIOLOGICAL ACTIVITY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, ADMINISTERED INTRA MUSCULARLY EVERY 6 WEEKS IN ACROMEGALIC PATIENTS
EUCTR2007-004162-41-HU / Not yet recruitingNot Applicable
SAFETY AND BIOLOGICAL ACTIVITY OF A NEW PROLONGED RELEASE FORMULATION OF OCTREOTIDE ACETATE, C2L-OCT-01 PR, ADMINISTERED INTRA MUSCULARLY EVERY 6 WEEKS IN ACROMEGALIC PATIENTS
100 Clinical Results associated with C2L-OCT-01 PR
Login to view more data
100 Translational Medicine associated with C2L-OCT-01 PR
Login to view more data
100 Patents (Medical) associated with C2L-OCT-01 PR
Login to view more data
100 Deals associated with C2L-OCT-01 PR
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AcromegalyPhase 3
BY
Ambrilia Biopharma, Inc.
01 Apr 2007
AcromegalyPhase 3
UA
Ambrilia Biopharma, Inc.
01 Apr 2007
AcromegalyPhase 3
RS
Ambrilia Biopharma, Inc.
01 Apr 2007
AcromegalyPhase 3
HU
Ambrilia Biopharma, Inc.
01 Apr 2007
AcromegalyPhase 3
RS
Ambrilia Biopharma, Inc.
01 Apr 2007
AcromegalyPhase 3
UA
Ambrilia Biopharma, Inc.
01 Apr 2007
AcromegalyPhase 3
RO
Ambrilia Biopharma, Inc.
01 Apr 2007
AcromegalyPhase 3
RO
Ambrilia Biopharma, Inc.
01 Apr 2007
AcromegalyPhase 3
HU
Ambrilia Biopharma, Inc.
01 Apr 2007
AcromegalyPhase 3
BY
Ambrilia Biopharma, Inc.
01 Apr 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free